CL2016003290A1 - Tratamiento de hipertrigliceridemia severa. - Google Patents

Tratamiento de hipertrigliceridemia severa.

Info

Publication number
CL2016003290A1
CL2016003290A1 CL2016003290A CL2016003290A CL2016003290A1 CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1 CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1
Authority
CL
Chile
Prior art keywords
treatment
severe hypertriglyceridemia
severe
hypertriglyceridemia
hypertrigliceridemia
Prior art date
Application number
CL2016003290A
Other languages
English (en)
Spanish (es)
Inventor
Pol Boudes
Yun-Jung Choi
Robert L Martin
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of CL2016003290A1 publication Critical patent/CL2016003290A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2016003290A 2014-06-26 2016-12-22 Tratamiento de hipertrigliceridemia severa. CL2016003290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26

Publications (1)

Publication Number Publication Date
CL2016003290A1 true CL2016003290A1 (es) 2017-09-08

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003290A CL2016003290A1 (es) 2014-06-26 2016-12-22 Tratamiento de hipertrigliceridemia severa.

Country Status (16)

Country Link
US (1) US20150374649A1 (index.php)
EP (1) EP3160458A1 (index.php)
JP (1) JP2017519028A (index.php)
KR (1) KR20170020514A (index.php)
CN (1) CN106470675A (index.php)
AU (1) AU2015279905A1 (index.php)
BR (1) BR112016028918A2 (index.php)
CA (1) CA2951280A1 (index.php)
CL (1) CL2016003290A1 (index.php)
EA (1) EA201790091A1 (index.php)
HK (1) HK1231380A1 (index.php)
IL (1) IL249757A0 (index.php)
MX (1) MX2016017081A (index.php)
PH (1) PH12016502415A1 (index.php)
SG (1) SG11201610243YA (index.php)
WO (1) WO2015200580A1 (index.php)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3119384T3 (en) 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP6865038B2 (ja) 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MY205171A (en) * 2017-12-21 2024-10-04 Kowa Co Methods of treatment of hypertriglyceridemia
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (en) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP2552441B1 (en) * 2010-03-30 2016-05-04 Novartis AG Uses of dgat1 inhibitors

Also Published As

Publication number Publication date
CA2951280A1 (en) 2015-12-30
PH12016502415A1 (en) 2017-02-27
EP3160458A1 (en) 2017-05-03
WO2015200580A1 (en) 2015-12-30
MX2016017081A (es) 2017-05-01
AU2015279905A1 (en) 2017-02-02
JP2017519028A (ja) 2017-07-13
US20150374649A1 (en) 2015-12-31
EA201790091A1 (ru) 2017-07-31
BR112016028918A2 (pt) 2017-08-22
SG11201610243YA (en) 2017-01-27
HK1231380A1 (zh) 2017-12-22
KR20170020514A (ko) 2017-02-22
IL249757A0 (en) 2017-02-28
CN106470675A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
CL2016003290A1 (es) Tratamiento de hipertrigliceridemia severa.
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2016001215A1 (es) Tratamiento de hipercolesterolemia familiar homocigota.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
LT3429571T (lt) Sd1 inhibitorių deriniai, skirti neoplastinių ligų gydymui
CL2016002971A1 (es) Combinación.
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
IL249663A0 (en) Process for the preparation of substituted oxiranes and triazoles
MX2017002972A (es) Pirrolopirimidinas para usarse en la infeccion por el virus de la gripe.
AR103680A1 (es) Inhibidores selectivos de bace1
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
GB201413826D0 (en) Plasma treatment of an infected nail or infected skin
EP3092013A4 (en) Sterilization of topical antiseptic solutions
MX367478B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
EA201791174A1 (ru) Антимикотическое соединение
MX2018007296A (es) Compuestos de isoindol.
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
SI3080311T1 (sl) Postopek za proizvodnjo visokotrdnostnega dupleks nerjavnega jekla
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы